"Rituximab" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A murine-derived monoclonal antibody and ANTINEOPLASTIC AGENT that binds specifically to the CD20 ANTIGEN and is used in the treatment of LEUKEMIA; LYMPHOMA and RHEUMATOID ARTHRITIS.
Descriptor ID |
D000069283
|
MeSH Number(s) |
D12.776.124.486.485.114.224.075.785 D12.776.124.790.651.114.224.075.785 D12.776.377.715.548.114.224.284.785
|
Concept/Terms |
Rituximab- Rituximab
- CD20 Antibody, Rituximab
- Rituximab CD20 Antibody
|
Below are MeSH descriptors whose meaning is more general than "Rituximab".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Blood Proteins [D12.776.124]
- Immunoproteins [D12.776.124.486]
- Immunoglobulins [D12.776.124.486.485]
- Antibodies [D12.776.124.486.485.114]
- Antibodies, Monoclonal [D12.776.124.486.485.114.224]
- Antibodies, Monoclonal, Murine-Derived [D12.776.124.486.485.114.224.075]
- Rituximab [D12.776.124.486.485.114.224.075.785]
- Serum Globulins [D12.776.124.790]
- Immunoglobulins [D12.776.124.790.651]
- Antibodies [D12.776.124.790.651.114]
- Antibodies, Monoclonal [D12.776.124.790.651.114.224]
- Antibodies, Monoclonal, Murine-Derived [D12.776.124.790.651.114.224.075]
- Rituximab [D12.776.124.790.651.114.224.075.785]
- Globulins [D12.776.377]
- Serum Globulins [D12.776.377.715]
- Immunoglobulins [D12.776.377.715.548]
- Antibodies [D12.776.377.715.548.114]
- Antibodies, Monoclonal [D12.776.377.715.548.114.224]
- Antibodies, Monoclonal, Murine-Derived [D12.776.377.715.548.114.224.284]
- Rituximab [D12.776.377.715.548.114.224.284.785]
Below are MeSH descriptors whose meaning is more specific than "Rituximab".
This graph shows the total number of publications written about "Rituximab" by people in this website by year, and whether "Rituximab" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2009 | 0 | 2 | 2 |
2010 | 0 | 1 | 1 |
2016 | 2 | 0 | 2 |
2018 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Rituximab" by people in Profiles.
-
Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial. J Clin Oncol. 2018 02 10; 36(5):454-462.
-
Randomized Trial Comparing R-CHOP Versus High-Dose Sequential Chemotherapy in High-Risk Patients With Diffuse Large B-Cell Lymphomas. J Clin Oncol. 2016 11 20; 34(33):4015-4022.
-
Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy. Blood. 2016 07 21; 128(3):395-404.
-
Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia. J Clin Oncol. 2010 Jul 01; 28(19):3115-21.
-
Girls homozygous for an IL-2-inducible T cell kinase mutation that leads to protein deficiency develop fatal EBV-associated lymphoproliferation. J Clin Invest. 2009 May; 119(5):1350-8.
-
Reassessment of treatment modalities for paediatric patients with chronic immune thrombocytopenia. Hamostaseologie. 2009 May; 29(2):171-6.